Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Licensing
11:30 AM ET 07/20/2026
Tempus AI (TEM) pledged to buy cancer diagnostics outfit Personalis (PSNL) for $1.5 billion on Monday. But shares of both medtech companies skidded. The deal follows a rumor last week that Merck (MRK) and others, including potentially Tempus AI, had expressed interest in buying Personalis. Personalis makes a blood test that screens for circulating tumor DNA, a marker that a…
Tempus AI acquires Personalis for $1.5 billion to expand cancer MRD testing capabilities, targeting a $20 billion market with…
Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD market.
Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in…
Personalis stock popped Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company.
Tempus AI strikes $1.5B deal for Personalis, betting big on AI-powered cancer detection
Why Is Tempus AI Stock Volatile Tuesday? - Personalis (NASDAQ:PSNL), Tempus AI (NASDAQ:TEM)
Tempus to acquire cancer test maker Personalis for $1.5B
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition - Personalis (NASDAQ:PSNL), Tempu
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
